Ebola and Marburg hemorrhagic fevers are acute viral diseases that often lead to severe illness and death in humans and other primates. The infections typically affect multiple organs in the body and are often accompanied by hemorrhage (bleeding). Once the virus has been transmitted from an animal host to a human, it can then spread through person-to-person contact.
Why Is the Study of Ebola & Marburg a Priority for NIAID?
Marburg hemorrhagic fever was first recognized in 1967, when laboratory workers in Germany and Yugoslavia developed a hemorrhagic illness after handling tissue from green monkeys. The outbreak resulted in 31 infections and 7 deaths. Researchers later identified the cause as a never-before-seen filovirus, termed “Marburg” after one of the outbreak locations.
Eleven years later, Ebola virus was identified when two outbreaks of hemorrhagic fever occurred in northern Zaire (now the Democratic Republic of Congo) and southern Sudan. The causes of the outbreaks were identified as two different species of another novel filovirus, called “Ebola” after a river in northern Zaire. Both species proved to be highly lethal, as 90 percent of the Zairian cases and 50 percent of the Sudanese cases resulted in death.
How Is NIAID Addressing This Critical Topic?
NIAID researchers and NIAID-supported scientists at external institutions are studying many aspects of the Ebola and Marburg viruses and how they cause disease. This includes seeking better ways to diagnose and treat Ebola virus disease and Marburg fevers and using applied research to develop vaccines, treatments, and diagnostics.
To learn about risk factors for Ebola and Marburg, as well as learn current prevention and treatment strategies visit the MedlinePlus Ebola site or the visit the Centers for Disease Control and Prevention Marburgh hemorrhagic fever site.
NIAID is supporting the development of multiple Ebola vaccine candidates that are in various stages of development, such as NIAID/GSK Investigational Ebola Vaccine (cAd3-EBOZ), rVSV-ZEBOV Investigational Ebola Vaccine, and more.
NIAID is also supporting the development of improved diagnostics to detect Ebola virus infection, including those that can provide rapid identification and can be deployed at the point of care where Ebola virus outbreaks occur.
NIAID is advancing research on several investigational Ebola treatments in different stages of development such as, ZMapp, an investigational Ebola treatment “cocktail” of three different proteins, and BCX4430, an investigational small molecule drug with broad-spectrum antiviral activity, including against Ebola.
Investigators hope to better understand the long-term health consequences of Ebola virus infection, determine if survivors develop immunity that will protect them from future Ebola virus infection, and assess whether previously Ebola-Virus-Disease-infected individuals can transmit the virus to close contacts and sexual partners.
NIAID Study of VSV Ebola Virus Vaccine Shows No Transmission Threat to Livestock
Scientists have used vesicular stomatitis virus (VSV) as an experimental vaccine delivery system against infectious diseases, including Ebola, Marburg, and Lassa fever viruses—but could people inoculated with those vaccines become a threat to transmit VSV to livestock?
Latest News Releases
NIH Begins Study of Vaccine to Protect Against Mosquito-Borne Diseases, February 21, 2017
NIH Scientists Identify Early Impact of Ebola Virus on Immune System, January 17, 2017